retatrutide phase 2 obesity trial results hits 28% weight loss in 3 Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

Trial candidates are generally adults with type 2 diabetes and a BMI over 30 who have not achieved adequate glucose or weight control with standard therapies like metformin or a single GLP-1 agonist

About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features 2026 Google LLC Mosbeau Official - YouTube

The index event was defined as the initiation of an SGLT2i in the SGLT2i cohort and a GLP-1 RA in the GLP-1 RA cohort

*VRN = Valores de referencia de nutrientes

A good candidate for glutathione IV therapy is anyone experiencing depleted antioxidant levels, elevated oxidative stress, or specific wellness goals that benefit from rapid glutathione replenishment